Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours.



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/14/2019
Start Date:March 7, 2019
End Date:May 21, 2021
Contact:Boehringer Ingelheim
Email:clintriage.rdg@boehringer-ingelheim.com
Phone:1-800-243-0127

Use our guide to learn which trials are right for you!

An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 naïve and PD-(L)1 Pretreated Patient Populations With Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy

The aim of this study is to assess the efficacy of BI 754091 in combination with other
checkpoint inhibitors or anticancer medications in diverse tumour type cohorts.


Inclusion Criteria

Master Protocol:

- Provision of signed and dated, written Master informed consent form (ICF) prior to any
trial-specific procedures, sampling, or analyses.

- Patient ≥18 years of age at the time of signature of the ICF.

- Eastern Cooperative Oncology Group (ECOG) score: 0 to 1.

- Patient must agree to a pre-treatment biopsy (if archival tissue is not available) and
on-treatment tumour biopsy.

- Life expectancy of at least 12 weeks after the start of the treatment according to the
Investigator's judgement.

- Male or female patients. Women of childbearing potential (WOCBP)1 and men able to
father a child must be willing and able to use highly effective methods of birth
control (that result in a low failure rate of less than 1% per year when used
consistently and correctly) during trial participation and for at least 6 months after
the last administration of trial medication.

Module A:

-Histologically confirmed diagnosis of one of the following cohorts:

- Cohort 1 GEC - Locally advanced, unresectable or metastatic gastric adenocarcinoma or
gastro oesophageal adenocarcinoma (GEC) (defined as primary tumour localisation below
the gastro oesophageal junction (GEJ) with prior anti-PD-1 or anti-PD-L1 based treated
tumour.

- Cohort 2 Patients with secondary resistance to anti-PD-1 or anti-PD-L1 based therapy:
Any advanced or metastatic solid tumour with previously anti-PD-1 or anti-PD-L1 based
treatment who progressed after achieving benefit

- Cohort 3 Patients with primary resistance to anti-PD-1 or anti-PD-L1 based therapy:
Select advanced or metastatic solid tumour types with previous anti-PD- 1/PD-L1 based
treated tumour without achieving benefit.

- All patients must have measurable lesions according to RECIST v1.1

- Patient must agree to pre- and on-treatment tumour biopsies. If archived tumour tissue
is available from the last treatment failure, sections may be supplied instead of a
pre-treatment biopsy.

Exclusion Criteria

Master Protocol:

- Any investigational treatment anti-tumour treatment within 4 weeks or within 5
half-life periods (whichever is shorter) prior to the initiation of trial treatment.

- A maximum of one anti-PD-(L)1-based treatment regimen prior to entering study

- Major surgery ('major' according to the Investigator's assessment) performed within 12
weeks prior to first trial treatment or planned within 12 months after screening,
e.g., hip replacement.

- Known history of severe hypersensitivity reactions to other mAbs or known
hypersensitivity to the trial drugs or their excipients.

- Known presence of symptomatic central nervous system (CNS) metastases, unless
asymptomatic and off corticosteroids and/or anticonvulsant therapy for at least 2
weeks prior to start of treatment.

- Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within
4 weeks prior to the first dose of study treatment.

- Active autoimmune disease or a documented history of autoimmune disease, except
vitiligo or resolved childhood asthma/atopy, or a patient removed from previous
anti-PD-1 or anti-PD-L1 therapy because of a severe immune-related adverse event
(irAE).

Module A:

- Previous treatment with an anti-LAG-3 agent

- The use of systemic steroids

- Autoimmune disease
We found this trial at
1
site
9500 Gilman Dr
La Jolla, California 92093
(858) 534-2230
Phone: +001 (858) 246-1102
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials